Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.47), $0.25 better than the analyst estimate of ($1.72). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.